Mercaptor Discoveries

Mercaptor discovered and is developing a range of novel drug therapies to treat neurodegenerative conditions and brain injuries such as, but not limited, to Parkinson’s disease, ALS, traumatic brain injury (TBI), CTE, and more, using its groundbreaking, newly-discovered drug molecules called “captons.” This breakthrough is akin to some of medicine’s biggest paradigm shifters, including vaccines (1796), antibiotics (1928), antibodies (1959), and kinase inhibitors (1990).

Captons isolate brain diseases and injuries, preventing progression into healthy parts of the brain. This unprecedented approach also applies to diseases outside the brain.

Mercaptor’s Team Builds Biotech Success

Mercaptor’s founders have an extensive track record and decades of experience, including the establishment of a successful biotech company, Raptor Pharmaceuticals, in 2006. Raptor was purchased in 2016 for almost $900M.

This same team formed Mercaptor Discoveries and is working to bring captons to the market.

In the course of the last 5 years working at Raptor Pharmaceuticals, Mercaptor’s founding scientists developed certain molecules, which led to the groundbreaking discovery of captons.



Captons Can Stop Excitotoxicity

As of now, drugs do not differentiate between healthy and diseased brain tissue. Captons do, acting only at the site of injury to treat excitotoxic stress where needed. Captons respond directly to toxins released during the process of excitotoxicity, either activating or remaining dormant in direct response to the pathology being treated. Currently, there are no drugs on the market that halt excitotoxicity, the underlying cause of neurodegeneration.

Acute and Chronic Brain Trauma Causes Excitotoxic Stress

Excitotoxicity arises when brain tissue is injured and the dying cells release toxins. The toxic release spreads to the neighboring cells, moving outward from the initial occurrence, increasing the area of brain damage. Certain injuries spread quickly while other types over many years. No drugs today treat brain damage and disease caused by excitotoxicity, which underlies TBI, CTE, alcohol withdrawal syndrome, spinal cord injury, stroke, and neurodegenerative disease, including multiple sclerosis (MS), Alzheimer's disease, ALS, Parkinson's disease, and Huntington’s disease. Captons prevent excitotoxicity through unprecedented and previously unknown chemistry discovered and developed by Mercaptor.

Captons Succeed Where Other Drugs Have Failed

Captons cross the blood-brain barrier and limit damage within brain tissue, stopping progression resulting from excitotoxicity. Excitotoxicity is the underlying cause of most brain injury and degeneration. Captons undergo an irreversible structural change only at sites of damage, in exact proportion to the damage itself.

This structural change creates neuroactive therapeutic molecules, already well-known to science and medicine for decades, but unusable as drugs due to their extremely low brain penetration and high toxicity from global distribution within the brain.

Market Share

  • > An estimated 5 million people in the United States, aged 65 years or older, have Alzheimer’s disease. This number may triple to over 13.8 million people by 2050.
  • > Approximately 500,000 people in the United States have Parkinson’s disease, with about 50,000 new diagnoses each year.
  • > Approximately 13,000 people in the United States have ALS, with 5,000 new diagnoses each year.
  • > An estimated 8 million people sustain traumatic brain injury annually. TBI has been associated with all of the conditions above.

Investment Opportunity

  • > The historical significance of Mercaptor’s ground-breaking proprietary discovery creates a remarkable investment opportunity.
  • > Mercaptor is a privately-held company, with efficient operations led by the same team of experienced biotech veterans that successfully founded and launched Raptor Pharmaceuticals, which was purchased in 2016 for almost $900M.
  • > Mercaptor’s efficient business model allows the majority of funds to be utilized in the development of science, avoiding excess overhead and operational costs.

For detailed information please contact:

CEO/Co-Founder Sara Isbell

phone: +1 (415) 298-1771